Brisbane, Australia – AcuraBio, the leading Australian biopharmaceutical CDMO, recently acquired by biotech investor Dr. Glenn Haifer and Ampersand Capital Partners, announced today the appointment of Carolyn Cheer as VP Business Development.
Book a meeting with Carolyn Cheer at Bio Partnering @JPM
Carolyn Cheer brings more than 25 years’ experience in clinical drug development to her role at AcuraBio.
Her career spans leadership positions in a range of internationally focussed contract research businesses including bioanalytical, central laboratory, and clinical research organisations. She has led teams in business development, marketing, client services, general management and clinical operations.
This follows recent appointments of other high-level experienced executives at AcuraBio including international biopharma executive Guillaume Herry as CEO, and Joanne Reichardt as Head of People & Culture.
AcuraBio has two decades of experience in innovative therapeutics for customers in the biotech, pharmaceutical, and animal health industries. The CDMO provides plasmid DNA, recombinant proteins, vaccines, and complex live biotherapeutic products to customers in emerging therapeutics.
CEO Guillaume Herry said the company was extremely pleased to attract such exceptional talent.
“Carolyn Cheer has extensive experience in the sector and will be a valuable business partner for servicing our current and future clients,” he said.
“Carolyn is passionate about supporting biopharma clients as they bring their innovative and life-saving new drug products to market.”
“While AcuraBio is highly regarded for our CDMO services, we are rapidly positioning the company with services including plasmid DNA production to provide world-class services for next-generation advanced therapeutics development.”
About AcuraBio
AcuraBio Pty Ltd is one of Australia’s most experienced biopharmaceutical CDMOs, offering trusted, client-focused services to both domestic and international clients for the past 20 years. AcuraBio offers significant quality, cost, and IP assurances for biopharma companies around the world. World-class researchers and proven facilities, a streamlined regulatory framework, generous tax incentives, and government funding make Australia a prime location for biotech research. AcuraBio has the following operating licenses: TGA (Australian FDA equivalent) license for the manufacture of human therapeutic APIs from biological and synthetic sources, APVMA (veterinary equivalent of the TGA) license for manufacture of sterile immunobiological products, OGTR license to produce products from genetically modified organisms, and a DAF facility license for import and use of biologic materials. Additional information about AcuraBio is available at www.acurabio.com.
About Ampersand Capital Partners
Founded in 1988, Ampersand is a middle market private equity firm with more than $3 billion of assets under management dedicated to growth-oriented investments in the healthcare sector. With offices in Boston and Amsterdam, Ampersand leverages its unique blend of private equity and operating experience in seeking to build value and drive strong long-term performance alongside its portfolio company management teams. Ampersand has helped build numerous market-leading companies across each of the firm’s core healthcare sectors. Additional information about Ampersand is available at www.ampersandcapital.com
